Communicating polygenic risk scores in the familial breast cancer clinic.
Guptaa KD, Gregory G, Meiser B, Kaur R, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, McInerney-Leo A, Young MA, James PA, Yanes T.
Patient Educ Couns. 2020 Mar 1:S0738-3991(21)001683. doi: 10.1016/j.pec.2021.02.046. Epub ahead of print.
Nouvelles AMMs : niraparib et olaparib en première ligne dans les cancers de l’ovaire [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Delaye M, Rodrigues M.
Bull Cancer. 2021 Feb 25:S0007-4551(21)00038-2. French. doi: 10.1016/j.bulcan.2021.01.003. Epub ahead of print.
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
Waddington T, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Romo H, Ghanem B, Gray S, Salgia R.
Clin Lung Cancer. 2021 Jan 27:S1525-7304(21)00012-7. doi: 10.1016/j.cllc.2021.01.009. Epub ahead of print.